Cover Image
Market Research Report
Product code 
1001804

Connected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others),

Published: | Roots Analysis | 307 Pages | Delivery time: 1-2 business days

Price

Back to Top
Connected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others),
Published: January 31, 2021
Roots Analysis
Content info: 307 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Connected / Smart Drug Delivery Systems
Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030.

Overview:

Over the years, the rise in global disease burden has prompted healthcare providers to incline towards home-based care. In this context, as medical technology developers strive to make their offerings more patient centric, self-medication enabling products are in demand. According to an article published in March 2020, which was focused on the growing prominence of telehealth solutions during the COVID-19 pandemic, close to 85% patients in the US demonstrated preference for virtual consultations over direct interactions with healthcare providers. Presently, the widespread availability of affordable connectivity solutions, such as Bluetooth, Near Field Communication (NFC), Infrared (IR) and Radio Frequency Identification (RFID) is driving a fast-growing, hybrid products market, of which the pharmaceutical industry is also an emerging stakeholder. One of the major challenges associated with home-based care is poor adherence to prescribed medication regimens, which has been shown to be directly associated with poor treatment-related outcomes, additional healthcare costs. In order to address the aforementioned concerns, the healthcare industry has been putting in a lot of effort towards developing the means to simplify self-medication and deploy modern technology solutions to make home-based care more effective. Connected drug delivery devices, capable of capturing, storing and transmitting patient health and medication usage data to healthcare providers, are a result of recent innovation in this domain. The use of such advanced drug delivery devices has, so far, been demonstrated to improve disease management at home, enabling healthcare professional to periodically monitor compliance to therapy.

There are several connected healthcare products available in the market, and many more are under development, for use across multiple therapeutic areas, including (but not limited to) metabolic disorders, respiratory disorders and neurological disorders. Further, innovators in this domain are identifying ways to incorporate a variety of additional features, such as provisions for audiovisual / tactile feedback, error alerts, and software that can assist patients in dose titration, into their proprietary offerings. Presently, there are many smart versions of medication inhalers, handheld / wearable injectors, drug delivery pumps, and implantable devices, in the market. As patients continue to adopt such smart solutions, it is projected that their overall spending on healthcare is likely to reduce. Considering that over 2.8 billion individuals are estimated to own a smartphone in 2020, it is safe to infer that this key demographic of likely connected medical device users is growing at a significant pace. We believe that in the coming years, growth in this domain is likely to be sustained by an increasing demand for such connected solutions, especially from patients with chronic diseases / disorders, who need to medicate on a frequent basis.

Scope of the Report:

The “Connected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report features an extensive study of the current landscape and future outlook of the growing market for connected drug delivery devices that are either already commercialized or are under development. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of more than 65 connected drug delivery devices based on a number of relevant parameters such as
  • Type of device, namely connected inhalers, connected handheld injectors (connected pen injectors, connected autoinjectors and connected needle-free injectors) and connected wearable injectors (connected insulin pumps and connected patch pumps)
  • Status of development (approved / launched or under development)
  • Mode of drug delivery (injectable, inhalation and oral)
  • Targeted therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, hormonal disorders and others)
  • Type of connectivity solution offered,
  • Other key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts).

In addition, the chapter includes information on the device developers, including details on year of establishment, company size and location of headquarters.

  • A detailed assessment of the current market landscape of around 25 add-on sensors for conventional devices, featuring information on status of development (approved / launched or under development), area of application (inhalers, pen injectors, autoinjectors, smart pills, pre-filled syringes and eye droppers), along with details on type of connectivity solution and key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts). In addition, the chapter includes information on the device developers, including details on year of establishment, company size and location of headquarters.
  • A comprehensive competitiveness analysis of connected drug delivery systems (connected inhalers, connected handheld injectors and connected wearable injectors) and add-on sensors, taking into consideration various relevant parameters, such as supplier strength (company size) and relative competitiveness of the connected devices (audio / visual alerts, availability of companion mobile application and web portal, data storage / cloud platform, type of connectivity solution offered, and rechargeability / battery backup features)
  • Tabulated profiles of some of the prominent players in the industry (based on a proprietary shortlisting criteria), highlighting a brief overview of the company, financial information (if available), details related to its connected drug delivery devices portfolio, and recent developments and an informed future outlook.
  • A detailed analysis of more than 95 clinical studies (completed, ongoing and planned) of various connected drug delivery devices and add-on sensors, based on multiple parameters, such as type of device, trial registration year, trial phase, trial status, type of sponsor / collaborator, targeted therapeutic area, study design, type of allocation, type of intervention model, type of masking and primary purpose of the trial. Further, the chapter includes information on regional distribution of clinical trials, number of patients enrolled, leading industry players and leading connected drug delivery solutions (in terms of number of registered trials).
  • An analysis of the partnerships that have been inked by various stakeholders in this domain, during the period between 2015 and 2020 (till August), based on several parameters, such as year of agreement, type of partnership (acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others). The chapter also highlights analysis based on year of partnership, type of partnership, type of connected device and most active player(s) (in terms of number of partnerships inked). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2020, highlighting both intercontinental and intracontinental partnership activity.
  • A detailed analysis of the funding and investments that have been made in this domain; the analysis covers information on different types of funding, such as seed financing, venture capital financing, debt financing, equity financing, grants / awards and subsequent offerings, at various stages of development in companies that are focused on developing connected drug delivery devices and add-on sensors. In addition, the chapter highlights analysis based on number of funding instances, amount invested, type of funding, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical analysis by amount invested.
  • A detailed discussion on the various steps of the supply chain model, namely R&D development, product manufacturing and assembly, product distribution, marketing and sales and post market surveillance of the connected drug delivery devices and the cost requirements across each of the aforementioned stages.
  • An insightful discussion on the impact of COVID-19 pandemic on the overall connected drug delivery devices market. In addition, it features a brief discussion on the key initiatives undertaken by key pharma players and key strategies to mitigate the challenges associated with connected drug delivery devices market.
  • A summary of the various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and connected / smart drug delivery devices) across different geographical regions, such as, North America, Europe, Latin America, Asia Pacific and Middle East.
  • Detailed case studies on the prevalent chronic disease indications, featuring disease epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatment regimens and historical efforts for drug development along with details on the evolution of connected drug delivery devices / strategies for improving therapy adherence.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall connected drug delivery device industry.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in mid to long-term, for the period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of solution (connected drug delivery devices and add-on sensors), [B] type of product (connected inhalers, connected handheld injectors and connected wearable injectors), [C] therapeutic areas (metabolic disorders, neurological disorders, respiratory disorders, and others), and [D] route of administration (injectable and inhalable), and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). To account for the uncertainties associated with the development of these connected drug delivery devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Shaul Eitan (Chief Executive Officer, Avoset Health)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Michael Hooven (President and Chief Executive Officer, Enable Injections)
  • Gaurav Patel (Chief Executive Officer & Co-Founder, Cognita Labs)
  • Menachem Zucker (Vice President & Chief Scientist, Elcam Medical)
  • Mindy Katz (Vice President, Marketing and Alliance Management, Sorrel Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President Strategic Partnerships and Business Development, West Pharmaceutical Services)
  • Neil Williams (Director of Front-end Innovation and Head of Connected Health, Phillips-Medisize)
  • Anonymous (Advisor, Strategy and Business Development, etectRx)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading developers of connected / smart drug delivery systems?
  • What are the popular types of drug delivery devices that are currently being marketed / developed in this domain?
  • What are the novel / advanced features that device developers are incorporating in their respective devices, to maintain a competitive edge in the market?
  • What is the relative competitiveness of different connected solutions across several device segments?
  • What kind of partnership models are commonly being adopted by stakeholders in this industry?
  • What is the trend in capital investments in the connected drug delivery device market?
  • What is the overall cost distribution across the value chain of connected drug delivery devices?
  • What is the impact of COVID-19 outbreak on connected drug delivery devices market?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to connected drug delivery devices market?

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of smart / connected drug delivery devices, that are being developed or commercialized.

Chapter 3 provides a general overview about the connected drug delivery devices, along with the key design features and development process of connected devices. Further, it provides detailed information on the segmentation of connected devices, based on the type of device and type of technology used. The chapter also highlights various regulatory guidelines laid down for connected drug delivery devices. It further discusses the advantages and limitations of connected drug delivery devices, along with a discussion on the future trends that are likely to impact this emerging market.

Chapter 4 includes a detailed analysis of the current market landscape of over 65 connected drug delivery devices that are either commercialized or under different stages of development. The chapter includes the information and analyses based on a number of relevant parameters such as such as type of device, namely connected inhalers, connected handheld injectors (connected pen injectors, connected autoinjectors and connected needle-free injectors) and connected wearable injectors (connected insulin pumps and connected patch pumps), status of development (approved / launched or under development), mode of drug delivery (injectable, inhalation and oral), targeted therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, hormonal disorders and others), type of connectivity solution offered, information on key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts) . In addition, the chapter includes information on the overall device developers, including details on year of establishment, company size, location of headquarters, type of device offered and leading players. Further, the chapter also highlights the information on device developers across each device category (connected inhalers, connected handheld injectors and connected wearable injectors) with the analysis on status of development, key device specifications, year of establishment, company size and location of the headquarters.

Chapter 5 includes a detailed analysis of the current market landscape of around 25 add-on sensors for conventional drug delivery devices, including smart ingestible sensors (smart pills), along with the information on status of development (approved / launched or under development), area of application (inhalers, pen injectors, autoinjectors, smart pill, pre-filled syringe and eye droppers), along with details on type of connectivity solution and key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts). In addition, the chapter includes information on the device developers, including details on year of establishment, company size and location of headquarters.

Chapter 6 presents a product competitiveness analysis of all the connected drug delivery systems and add-on sensors, taking into consideration various relevant parameters, such as supplier strength (company size) and relative competitiveness of the connected devices (audio / visual alerts, availability of companion mobile application and web portal, data storage / cloud platform, type of connectivity solution offered, and rechargeability / battery backup features). The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 7 features tabulated profiles of some of the prominent stakeholders in the connected drug delivery systems market. Each profile features a brief overview of the company, its financial information (if available), details related to its connected drug delivery devices portfolio and recent developments and an informed future outlook.

Chapter 8 provides a detailed analysis of more than 95 completed, ongoing and planned clinical studies of various connected drug delivery solutions and add-on sensors, based on the various relevant parameters, such as type of device, trial recruitment status, trial registration year, trial phase, trial status, type of sponsor / collaborator, targeted therapeutic area, study design, type of allocation, type of intervention model, type of masking and primary purpose of the trial. Further, the chapter includes information on regional distribution of trials, number of patients enrolled, leading industry player and leading connected drug delivery solutions (in terms of number of registered trials).

Chapter 9 features an elaborate analysis of the recent partnerships and collaborations that have been inked amongst players in this market, during the period between 2015 and 2020 (till August), covering several partnership models, namely acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others, that have been adopted by industry stakeholders in this domain. The chapter highlights analysis based on year of partnerships, type of partnership, type of connected device and most active player(s) (in terms of number of partnerships inked). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2020, highlighting both intercontinental and intracontinental partnership activity.

Chapter 10 provides information on the funding and investments that have been made in both smart drug delivery systems and smart add-on sensors in the recent years. The chapter includes details on different types of funding, such as seed financing, venture funding, debt financing and grants, received by companies, highlighting the growing interest of the venture capital community and other strategic investors in this domain. The chapter highlights analysis based on number of funding instances, amount invested, type of funding, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical analysis by amount invested.

Chapter 11 presents a value chain analysis featuring a discussion on various steps of the development operations, namely R&D development, product manufacturing and assembly, product distribution and marketing and sales and post market surveillance of a connected drug delivery device and the cost requirements across each of the aforementioned stages.

Chapter 12 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of novel solutions, indication / region specific adoption trends, and competitive landscape. We have provided an informed estimate on the likely evolution of connected drug delivery devices and add-on sensors. In addition, we have segmented the market by type of product (connected inhalers, connected handheld injectors, and connected wearable injectors), therapeutic areas (metabolic disorders, neurological, respiratory disorders and others), route of administration (injectable and inhalable), and geography (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 highlights the impact of COVID-19 pandemic on the overall connected drug delivery device market. In addition, it features a brief discussion on the key initiatives undertaken by key pharma players and key strategies to mitigate the challenges associated with connected drug delivery devices market.

Chapter 14 provides information on various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions, such as, North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 15 features case study on the most common disease indications across metabolic disorders and respiratory disorders. Each case study features a detailed description of the disease, its epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatments for the disease and history of drug development along with the evolution of delivery devices / strategies focused on improving therapy adherence.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry's evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall connected drug delivery device market.

Chapter 17 summarizes the overall report. The chapter provides our independent opinion on the connected drug delivery devices market, based on the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of our conversations held with Shaul Eitan (Chief Executive Officer, Avoset Health), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Michael Hooven (President and Chief Executive Officer, Enable Injections), Gaurav Patel (Chief Executive Officer & Co-Founder, Cognita Labs), Menachem Zucker (Vice President & Chief Scientist, Elcam Medical), Mindy Katz (Vice President, Marketing and Alliance Management, Sorrel Medical), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President Strategic Partnerships and Business Development, West Pharmaceutical Services), Neil Williams (Director of Front-end Innovation and Head of Connected Health, Phillips-Medisize) and Anonymous (Advisor, Strategy and Business Development, etectRx).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Connected / Smart Drug Delivery Systems
  • 3.3. Key Design Features and Development Process
  • 3.4. Classification of Connected / Smart Drug Delivery Systems
    • 3.4.1. Based on Type of Device
    • 3.4.2. Based on Type of Technology
  • 3.5. Regulatory Guidelines for Connected / Smart Drug Delivery Systems
  • 3.6. Advantages and Limitations
  • 3.7. Future Perspectives

4. CONNECTED / SMART DRUG DELIVERY SYSTEMS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Connected / Smart Drug Delivery Systems: Overall Market Landscape
    • 4.2.1. Analysis by Type of Device
    • 4.2.2. Analysis by Status of Development
    • 4.2.3. Analysis by Mode of Drug Delivery
    • 4.2.4. Analysis by Targeted Therapeutic Area
    • 4.2.5. Analysis by Key Device Specifications
      • 4.2.5.1. Audio / Visual Alerts
      • 4.2.5.2. Connectivity (USB, Bluetooth, NFC, WIFI, or Cellular)
      • 4.2.5.3. Companion Mobile Application
      • 4.2.5.4. Companion Web Portal
      • 4.2.5.5. Data Storage / Cloud Platform
      • 4.2.5.6. Rechargeable Battery / Battery Backup
      • 4.2.5.7. Reminder / Notifications / Alerts
    • 4.2.6. Connected / Smart Drug Delivery System Developers: Overall Market Landscape
      • 4.2.6.1. Analysis by Year of Establishment
      • 4.2.6.2. Analysis by Company Size
      • 4.2.6.3. Analysis by Location of Headquarters
      • 4.2.6.4 Leading Players: Analysis by Number of Connected / Smart Drug Delivery Systems
    • 4.2.7. Connected / Smart Inhalers: Overall Market Landscape
      • 4.2.7.1. Analysis by Status of Development
      • 4.2.7.2. Analysis by Key Device Specifications
      • 4.2.7.3. Analysis by Year of Establishment
      • 4.2.7.4. Analysis by Company Size
      • 4.2.7.5. Analysis by Location of Headquarters
    • 4.2.8. Connected / Smart Handheld Injectors: Overall Market Landscape
      • 4.2.8.1. Analysis by Status of Development
      • 4.2.8.2. Analysis by Key Device Specifications
      • 4.2.8.3. Analysis by Year of Establishment
      • 4.2.8.4. Analysis by Company Size
      • 4.2.8.5. Analysis by Location of Headquarters
    • 4.2.9. Connected / Smart Wearable Injectors: Overall Market Landscape
      • 4.2.9.1. Analysis by Status of Development
      • 4.2.9.2. Analysis by Key Device Specifications
      • 4.2.9.3. Analysis by Year of Establishment
      • 4.2.9.4. Analysis by Company Size
      • 4.2.9.5. Analysis by Location of Headquarters

5. ADD-ON SENSORS: MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Add-On Sensors: Overall Market Landscape
    • 5.2.1. Analysis by Status of Development
    • 5.2.2. Analysis by Area of Application
    • 5.2.3. Analysis by Key Device Specifications
    • 5.2.4. Analysis by Type of Connectivity Solution
    • 5.2.5. Add-On Sensor Developers: Overall Market Landscape
      • 5.2.5.1. Analysis by Year of Establishment
      • 5.2.5.2. Analysis by Company Size
      • 5.2.5.3. Analysis by Location of Headquarters
      • 5.2.5.4 Leading Players: Analysis by Number of Add-On Sensors

6. PRODUCT COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Methodology and Key Parameters
  • 6.3. Product Competitiveness Analysis: Connected Drug Delivery Devices and Add-On Sensors
    • 6.3.1. Product Competitiveness Analysis for Connected / Smart Inhalers
    • 6.3.2. Product Competitiveness Analysis for Connected / Smart Handheld Injectors
    • 6.3.3. Product Competitiveness Analysis for Connected / Smart Wearable Injectors
    • 6.3.4. Product Competitiveness Analysis for Add-On Sensors

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. BIOCORP
    • 7.2.1. Company Overview
    • 7.2.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Elcam Drug Delivery Devices (E3D)
    • 7.3.1. Company Overview
    • 7.3.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. Novo Nordisk
    • 7.4.1. Company Overview
    • 7.4.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Merck
    • 7.5.1. Company Overview
    • 7.5.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. Pneuma Respiratory
    • 7.6.1. Company Overview
    • 7.6.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. H&T Presspart
    • 7.7.1. Company Overview
    • 7.7.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. Nemera
    • 7.8.1. Company Overview
    • 7.8.2. Connected / Smart Drug Delivery Devices Portfolio
    • 7.8.3. Recent Developments and Future Outlook

8. CLINICAL TRIAL ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Connected / Smart Drug Delivery Systems and Add-On Sensors: Clinical Trial Analysis
    • 8.3.1. Analysis by Type of Device
    • 8.3.2. Analysis by Trial Registration Year
    • 8.3.3. Analysis by Trial Phase
    • 8.3.4. Analysis by Trial Status
    • 8.3.5. Analysis by Type of Sponsor / Collaborator
    • 8.3.6. Analysis by Targeted Therapeutic Area
    • 8.3.7. Analysis by Study Design
    • 8.3.8. Analysis by Number of Patients Enrolled and Trial Registration Year
    • 8.3.9. Geographical Analysis by Number of Clinical Trials
    • 8.3.10. Geographical Analysis by Number of Patients Enrolled
    • 8.3.11. Geographical Analysis by Trial Recruitment Status
    • 8.3.12. Leading Industry Players: Analysis by Number of Registered Trials
    • 8.3.13. Leading Connected / Smart Drug Delivery Systems and Add-On Sensors: Analysis by Number of Registered Trials

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Connected / Smart Drug Delivery Systems and Add-On Sensors: List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Type of Device
    • 9.3.4. Most Active Players: Analysis by Number of Partnerships
    • 9.3.5. Geographical Analysis
      • 9.3.5.1. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Connected / Smart Drug Delivery Systems and Add-On Sensors: Recent Funding Instances
    • 10.3.1. Analysis by Number of Funding Instances
    • 10.3.2. Analysis by Amount Invested
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
    • 10.3.5. Most Active Players: Analysis by Number of Funding Instances
    • 10.3.6. Most Active Investors: Analysis by Number of Instances
    • 10.3.7. Geographical Analysis by Amount Invested

11. VALUE CHAIN / COST PRICE ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Connected / Smart Drug Delivery Systems Value Chain
  • 11.3. Cost Distribution Across the Value Chain
    • 11.3.1. Concept Development and Proof of Concept
    • 11.3.2. Research and Product Development
    • 11.3.3 Clinical Trials
    • 11.3.4. Regulatory Approvals
    • 11.3.5. Manufacturing and Product Assembly
    • 11.3.6. Application Development
    • 11.3.7. Marketing and Sales

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Global Connected / Smart Drug Delivery Systems Market, 2020-2030 (By Value)
    • 12.3.1. Connected / Smart Drug Delivery Systems Market for Drug Delivery Devices, 2020-2030 (By Value)
    • 12.3.2. Connected / Smart Drug Delivery Systems Market for Add-On Sensors, 2020-2030 (By Value)
  • 12.4. Global Connected / Smart Drug Delivery Systems Market, 2020-2030 (By Volume)
    • 12.4.1 Connected / Smart Drug Delivery Systems Market for Drug Delivery Devices, 2020-2030 (By Volume)
    • 12.4.2 Connected / Smart Drug Delivery Systems Market for Add-On Sensors, 2020-2030 (By Volume)
  • 12.5. Global Connected / Smart Drug Delivery Systems Market: Distribution by Geography, 2020-2030 (By Value)
    • 12.5.1. Connected / Smart Drug Delivery Systems Market in North America, 2020-2030 (By Value)
    • 12.5.2. Connected / Smart Drug Delivery Systems Market in Europe, 2020-2030 (By Value)
    • 12.5.3. Connected / Smart Drug Delivery Systems Market in Asia-Pacific, 2020-2030 (By Value)
    • 12.5.4. Connected / Smart Drug Delivery Systems Market in MENA, 2020-2030 (By Value)
    • 12.5.5. Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, 2020-2030 (By Value)
  • 12.6. Global Connected / Smart Drug Delivery Systems Market: Distribution by Geography, 2020-2030 (By Volume)
    • 12.6.1. Connected / Smart Drug Delivery Systems Market in North America, 2020-2030 (By Volume)
    • 12.6.2. Connected / Smart Drug Delivery Systems Market in Europe, 2020-2030 (By Volume)
    • 12.6.3. Connected / Smart Drug Delivery Systems Market in Asia-Pacific, 2020-2030 (By Volume)
    • 12.6.4. Connected / Smart Drug Delivery Systems Market in MENA, 2020-2030 (By Volume)
    • 12.6.5. Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, 2020-2030 (By Volume)
  • 12.7. Global Connected / Smart Drug Delivery Systems Market: Distribution by Type of Product and Geography (By Value)
    • 12.7.1. Connected / Smart Drug Delivery Systems Market for Inhalers, 2020-2030 (By Value)
      • 12.7.1.1. Connected / Smart Drug Delivery Systems Market for Inhalers in North America, 2020-2030 (By Value)
      • 12.7.1.2. Connected / Smart Drug Delivery Systems Market for Inhalers in Europe, 2020-2030 (By Value)
      • 12.7.1.3. Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, 2020-2030 (By Value)
      • 12.7.1.4. Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, 2020-2030 (By Value)
      • 12.7.1.5. Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.7.2. Connected / Smart Drug Delivery Systems Market for Handheld Injectors, 2020-2030 (By Value)
      • 12.7.2.1. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, 2020-2030 (By Value)
      • 12.7.2.2. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, 2020-2030 (By Value)
      • 12.7.2.3. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, 2020-2030 (By Value)
      • 12.7.2.4. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, 2020-2030 (By Value)
      • 12.7.2.5. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.7.3. Connected / Smart Drug Delivery Systems Market for Wearable Injectors, 2020-2030 (By Value)
      • 12.7.3.1. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, 2020-2030 (By Value)
      • 12.7.3.2. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, 2020-2030 (By Value)
      • 12.7.3.3. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, 2020-2030 (By Value)
      • 12.7.3.4. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, 2020-2030 (By Value)
      • 12.7.3.5. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, 2020-2030 (By Value)
  • 12.8. Global Connected / Smart Drug Delivery Systems Market: Distribution by Type of Product and Geography (By Volume)
    • 12.8.1. Connected / Smart Drug Delivery Systems Market for Inhalers, 2020-2030 (By Volume)
      • 12.8.1.1. Connected / Smart Drug Delivery Systems Market for Inhalers in North America, 2020-2030 (By Volume)
      • 12.8.1.2. Connected / Smart Drug Delivery Systems Market for Inhalers in Europe, 2020-2030 (By Volume)
      • 12.8.1.3. Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, 2020-2030 (By Volume)
      • 12.8.1.4. Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, 2020-2030 (By Volume)
      • 12.8.1.5. Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.8.2. Connected / Smart Drug Delivery Systems Market for Handheld Injectors, 2020-2030 (By Volume)
      • 12.8.2.1. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, 2020-2030 (By Volume)
      • 12.8.2.2. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, 2020-2030 (By Volume)
      • 12.8.2.3. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, 2020-2030 (By Volume)
      • 12.8.2.4. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, 2020-2030 (By Volume)
      • 12.8.2.5. Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.8.3. Connected / Smart Drug Delivery Systems Market for Wearable Injectors, 2020-2030 (By Volume)
      • 12.8.3.1. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, 2020-2030 (By Volume)
      • 12.8.3.2. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, 2020-2030 (By Volume)
      • 12.8.3.3. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, 2020-2030 (By Volume)
      • 12.8.3.4. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, 2020-2030 (By Volume)
      • 12.8.3.5. Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, 2020-2030 (By Volume)
  • 12.9. Global Connected / Smart Drug Delivery Systems Market: Distribution by Type of Disorder and Geography (By Volume)
    • 12.9.1 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, 2020-2030 (By Value)
      • 12.9.1.1. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, 2020-2030 (By Value)
      • 12.9.1.2. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, 2020-2030 (By Value)
      • 12.9.1.3. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (By Value)
      • 12.9.1.4. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, 2020-2030 (By Value)
      • 12.9.1.5. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.9.2. Connected / Smart Drug Delivery Systems Market for Neurological Disorders, 2020-2030 (By Value)
      • 12.9.2.1. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, 2020-2030 (By Value)
      • 12.9.2.2. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, 2020-2030 (By Value)
      • 12.9.2.3. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, 2020-2030 (By Value)
      • 12.9.2.4. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in MENA, 2020-2030 (By Value)
      • 12.9.2.5. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.9.3. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, 2020-2030 (By Value)
      • 12.9.3.1. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, 2020-2030 (By Value)
      • 12.9.3.2. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, 2020-2030 (By Value)
      • 12.9.3.3. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (By Value)
      • 12.9.3.4. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, 2020-2030 (By Value)
      • 12.9.3.5. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.9.4. Connected / Smart Drug Delivery Systems Market for Other Disorders, 2020-2030 (By Value)
      • 12.9.4.1. Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, 2020-2030 (By Value)
      • 12.9.4.2. Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, 2020-2030 (By Value)
      • 12.9.4.3. Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, 2020-2030 (By Value)
      • 12.9.4.4. Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, 2020-2030 (By Value)
      • 12.9.4.5. Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, 2020-2030 (By Value)
  • 12.10. Global Connected / Smart Drug Delivery Systems Market: Distribution by Type of Disorder and Geography (By Volume)
    • 12.10.1. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, 2020-2030 (By Volume)
      • 12.10.1.1. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, 2020-2030 (By Volume)
      • 12.10.1.2. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, 2020-2030 (By Volume)
      • 12.10.1.3. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (By Volume)
      • 12.10.1.4. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, 2020-2030 (By Volume)
      • 12.10.1.5. Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.10.2. Connected / Smart Drug Delivery Systems Market for Neurological Disorders, 2020-2030 (By Volume)
      • 12.10.2.1. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, 2020-2030 (By Volume)
      • 12.10.2.2. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, 2020-2030 (By Volume)
      • 12.10.2.3. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, 2020-2030 (By Volume)
      • 12.10.2.4. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in MENA, 2020-2030 (By Volume)
      • 12.10.2.5. Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.10.3. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, 2020-2030 (By Volume)
      • 12.10.3.1. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, 2020-2030 (By Volume)
      • 12.10.3.2. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, 2020-2030 (By Volume)
      • 12.10.3.3. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (By Volume)
      • 12.10.3.4. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, 2020-2030 (By Volume)
      • 12.10.3.5. Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.10.4. Connected / Smart Drug Delivery Systems Market for Other Disorders, 2020-2030 (By Volume)
      • 12.10.4.1. Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, 2020-2030 (By Volume)
      • 12.10.4.2. Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, 2020-2030 (By Volume)
      • 12.10.4.3. Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, 2020-2030 (By Volume)
      • 12.10.4.4. Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, 2020-2030 (By Volume)
      • 12.10.4.5. Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, 2020-2030 (By Volume)
  • 12.11. Global Connected / Smart Drug Delivery Systems Market: Distribution by Route of Administration and Geography (By Value)
    • 12.11.1. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, 2020-2030 (By Value)
      • 12.11.1.1. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, 2020-2030 (By Value)
      • 12.11.1.2. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, 2020-2030 (By Value)
      • 12.11.1.3. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, 2020-2030 (By Value)
      • 12.11.1.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in MENA, 2020-2030 (By Value)
      • 12.11.1.5. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.11.2. Connected / Smart Drug Delivery Systems Market for Inhalable Medications, 2020-2030 (By Value)
      • 12.11.2.1. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, 2020-2030 (By Value)
      • 12.11.2.2. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, 2020-2030 (By Value)
      • 12.11.2.3. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, 2020-2030 (By Value)
      • 12.11.2.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, 2020-2030 (By Value)
      • 12.11.2.5. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, 2020-2030 (By Value)
    • 12.11.3. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, 2020-2030 (By Volume)
      • 12.11.3.1. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, 2020-2030 (By Volume)
      • 12.11.3.2. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, 2020-2030 (By Volume)
      • 12.11.3.3. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, 2020-2030 (By Volume)
      • 12.11.3.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in MENA, 2020-2030 (By Volume)
      • 12.11.3.5. Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, 2020-2030 (By Volume)
    • 12.11.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications, 2020-2030 (By Volume)
      • 12.11.4.1. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, 2020-2030 (By Volume)
      • 12.11.4.2. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, 2020-2030 (By Volume)
      • 12.11.4.3. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, 2020-2030 (By Volume)
      • 12.11.4.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, 2020-2030 (By Volume)
      • 12.11.4.4. Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, 2020-2030 (By Volume)

13. IMPACT OF COVID-19 PANDEMIC ON THE CONNECTED DRUG DELIVERY DEVICES MARKET

  • 13.1 Chapter Overview
  • 13.2. Impact on Future Market Opportunities for Connected / Smart Drug Delivery Systems
  • 13.3. Opportunities for Connected / Smart Drug Delivery Systems during the COVID-19 Pandemic
  • 13.4. Current Opinions and Recuperative Initiatives of Key Players
    • 13.4.1. SHL Group
    • 13.4.2. Novo Nordisk
    • 13.4.3. Elcam Drug Delivery Devices (E3D)
    • 13.4.4. Merck
  • 13.5. Key Strategies to Mitigate the Challenges Associated with Connected Drug Delivery Devices
    • 13.5.1. Strategies for Implementation in the Short / Mid Term
    • 13.5.2. Strategies for Implementation in the Long Term

14. REGULATORY LANDSCAPE

  • 14.1. Chapter Overview
  • 14.2. North America
    • 14.2.1. Regulatory Approval of Combination Products in the US
      • 14.2.1.1. Overview
      • 14.2.1.2. Historical Background
      • 14.2.1.3. Regulatory Bodies and Their Role in Product Approval
    • 14.2.2. Regulatory Approval of Combination Products in Canada
      • 14.2.2.1. Overview
      • 14.2.2.2. Regulatory Bodies and Their Role in Product Approval
  • 14.3. Europe
    • 14.3.1. Regulatory Approval of Combination Products in Europe
      • 14.3.1.1. Overview
      • 14.3.1.2. Regulatory Bodies and Their Role in Product Approval
  • 14.4. Latin America
    • 14.4.1. Regulatory Approval of Combination Products in Brazil
      • 14.4.1.1. Overview
      • 14.4.1.2. Regulatory Bodies and Their Role in Product Approval
    • 14.4.2. Regulatory Approval of Combination Products in Mexico
      • 14.4.2.1. Overview
      • 14.4.2.2. Regulatory Bodies and Their Role in Product Approval
    • 14.4.3. Regulatory Approval of Combination Products in Argentina
      • 14.4.3.1. Overview
      • 14.4.3.2. Regulatory Bodies and Their Role in Product Approval
  • 14.5. Asia-Pacific
    • 14.5.1. Regulatory Approval of Combination Products in Japan
      • 14.5.1.1. Overview
      • 14.5.1.2. Regulatory Bodies and Their Role in Product Approval
    • 14.5.2. Regulatory Approval of Combination Products in South Korea
      • 14.5.2.1. Overview
      • 14.5.2.2. Regulatory Bodies and Their Role in Product Approval
    • 14.5.3. Regulatory Approval of Combination Products in Australia
      • 14.5.3.1. Overview
      • 14.5.3.2. Regulatory Bodies and Their Role in Product Approval
    • 14.5.4. Regulatory Approval of Combination Products in China
      • 14.5.4.1. Overview
      • 14.5.4.2. Regulatory Bodies and Their Role in Product Approval
    • 14.5.5. Regulatory Approval of Combination Products in India
      • 14.5.5.1. Overview
      • 14.5.5.2. Regulatory Bodies and Their Role in Product Approval
  • 14.6. Middle East
    • 14.6.1. Regulatory Approval of Combination Products in Saudi Arabia
      • 14.6.1.1. Overview
      • 14.6.1.2. Regulatory Bodies and Their Role in Product Approval
    • 14.6.2. Regulatory Approval of Combination Products in United Arab Emirates
      • 14.6.2.1. Overview
      • 14.6.2.2. Regulatory Bodies and Their Role in Product Approval
  • 14.7. Connected Devices: Demonstrating Safety, Effectiveness and Performance
  • 14.8. Connected Devices: Ensuring Security of Data Captured

15. CASE STUDY

  • 15.1. Chapter Overview
  • 15.2. Case Study I: Diabetes
    • 15.2.1. Disease Description
    • 15.2.2. Disease Statistics
    • 15.2.3. Economic Burden due to Non-Adherence
    • 15.2.4. Evolution of Connected Drug Delivery Devices for Improving Adherence
  • 15.3. Case Study II: Asthma
    • 15.3.1. Disease Overview
    • 15.3.2. Disease Statistics
    • 15.3.3. Economic Burden due to Non-Adherence
    • 15.3.4. Evolution of Connected Drug Delivery Devices for Improving Adherence

16. SWOT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Comparison of SWOT Factors
    • 16.2.1. Strengths
    • 16.2.2. Weaknesses
    • 16.2.3. Opportunities
    • 16.2.4. Threats

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

  • 18.1. Chapter Overview
  • 18.2. Avoset Health
    • 18.2.1. Organization Snapshot
    • 18.2.2. Interview Transcript: Shaul Eitan, Chief Executive Officer
  • 18.3. Portal Instruments
    • 18.3.1. Organization Snapshot
    • 18.3.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer
  • 18.4. Enable Injections
    • 18.4.1. Organization Snapshot
    • 18.4.2. Interview Transcript: Michael Hooven, President and Chief Executive Officer
  • 18.5. Cognita Labs
    • 18.5.1. Organization Snapshot
    • 18.5.2. Interview Transcript: Gaurav Patel, Chief Executive Officer & Co-Founder
  • 18.6. Elcam Medical
    • 18.6.1. Organization Snapshot
    • 18.6.2. Interview Transcript: Menachem Zucker, Vice President & Chief Scientist
  • 18.7. Sorrel Medical
    • 18.7.1. Organization Snapshot
    • 18.7.2. Interview Transcript: Mindy Katz, Marketing and Alliance Management
  • 18.8. West Pharmaceutical Services
    • 18.8.1. Organization Snapshot
    • 18.8.2. Interview Transcript: Tiffany H. Burke, Director, Global Communications and Graham Reynolds, Vice President Strategic Partnerships and Business Development
  • 18.9. Phillips-Medisize
    • 18.9.1. Organization Snapshot
    • 18.9.2. Interview Transcript: Neil Williams, Director of Front-end Innovation and Head of Connected Health
  • 18.10. etectRx
    • 18.10.1. Organization Snapshot
    • 18.10.2. Interview Transcript: Anonymous, Advisor, Strategy and Business Development

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Internet of Things: Different Components of the Ecosystem
  • Figure 3.2 Connected / Smart Drug Delivery Systems: Data Capturing and Usage Framework
  • Figure 3.3 Technology Components of Connected / Smart Drug Delivery Systems
  • Figure 3.4 Connected / Smart Drug Delivery Systems: Distribution by Type of Technology Used
  • Figure 3.5 Advantages Offered by Connected / Smart Drug Delivery Devices
  • Figure 4.1 Connected / Smart Drug Delivery Systems: Distribution by Type of Device
  • Figure 4.2 Connected / Smart Drug Delivery Systems: Distribution by Status of Development
  • Figure 4.3 Connected / Smart Drug Delivery Systems: Distribution by Mode of Drug Delivery
  • Figure 4.4 Connected / Smart Drug Delivery Systems: Distribution by Route of Administration
  • Figure 4.4 Connected / Smart Drug Delivery Systems: Distribution by Targeted Therapeutic Area
  • Figure 4.5 Connected / Smart Drug Delivery Systems: Distribution by Key Device Specifications
  • Figure 4.6 Connected / Smart Drug Delivery Systems: Distribution by Availability of Audio / Visual Reminders
  • Figure 4.7 Connected / Smart Drug Delivery Systems: Distribution by Type of Connectivity (USB, Bluetooth, NFC, WIFI, or Cellular)
  • Figure 4.8 Connected / Smart Drug Delivery Systems: Distribution by Availability of Companion Mobile Application
  • Figure 4.9 Connected / Smart Drug Delivery Systems: Distribution by Availability of Companion Web Portal
  • Figure 4.10 Connected / Smart Drug Delivery Systems: Distribution by Availability of Data Storage / Cloud Platform
  • Figure 4.11 Connected / Smart Drug Delivery Systems: Distribution by Availability of Rechargeable Battery / Battery Backup
  • Figure 4.12 Connected / Smart Drug Delivery Systems: Distribution by Availability of Reminder / Notifications / Alerts
  • Figure 4.13 Connected / Smart Drug Delivery System Developers: Distribution by Year of Establishment
  • Figure 4.14 Connected / Smart Drug Delivery System Developers: Distribution by Company Size
  • Figure 4.15 Connected / Smart Drug Delivery System Developers: Distribution by Location of Headquarters
  • Figure 4.16 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Systems Offered
  • Figure 4.17 Connected / Smart Inhalers: Distribution by Status of Development
  • Figure 4.18 Connected / Smart Inhalers: Distribution by Key Device Specifications
  • Figure 4.19 Connected / Smart Inhaler Developers: Distribution by Year of Establishment
  • Figure 4.20 Connected / Smart Inhaler Developers: Distribution by Company Size
  • Figure 4.21 Connected / Smart Inhaler Developers: Distribution by Location of Headquarters
  • Figure 4.22 Connected / Smart Handheld Injectors: Distribution by Status of Development
  • Figure 4.23 Connected / Smart Handheld Injectors: Distribution by Key Device Specifications
  • Figure 4.24 Connected / Smart Handheld Injector Developers: Distribution by Year of Establishment
  • Figure 4.25 Connected / Smart Handheld Injector Developers: Distribution by Company Size
  • Figure 4.26 Connected / Smart Handheld Injector Developers: Distribution by Location of Headquarters
  • Figure 4.27 Connected / Smart Wearable Injectors: Distribution by Status of Development
  • Figure 4.28 Connected / Smart Wearable Injectors: Distribution by Key Device Specifications
  • Figure 4.29 Connected / Smart Wearable Injector Developers: Distribution by Year of Establishment
  • Figure 4.30 Connected / Smart Wearable Injector Developers: Distribution by Company Size
  • Figure 4.31 Connected / Smart Wearable Injector Developers: Distribution by Location of Headquarters
  • Figure 5.1 Add-On Sensors: Distribution by Status of Development
  • Figure 5.2 Add-On Sensors: Distribution by Area of Application
  • Figure 5.3 Add-On Sensors: Distribution by Type of Connectivity Solution
  • Figure 5.4 Add-On Sensors: Distribution by Key Device Specifications
  • Figure 5.5 Add-On Sensor Developers: Distribution by Year of Establishment
  • Figure 5.6 Add-On Sensors Developers: Distribution by Company Size
  • Figure 5.7 Add-On Sensors Developers: Distribution by Location of Headquarters
  • Figure 5.8 Most Active Players: Distribution by Number of Add-On Sensors Offered
  • Figure 6.1 Product Competitiveness Analysis: Connected / Smart Inhalers
  • Figure 6.2 Product Competitiveness Analysis: Connected / Smart Handheld Injectors
  • Figure 6.3 Product Competitiveness Analysis: Connected / Smart Wearable Injectors
  • Figure 6.4 Product Competitiveness Analysis: Add-On Sensors
  • Figure 8.1 Clinical Trial Analysis: Distribution by Type of Device
  • Figure 8.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011 to 2020 (Till August)
  • Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
  • Figure 8.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 8.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 8.7 Clinical Trial Analysis: Distribution by Number of Trials and Targeted Therapeutic Area
  • Figure 8.8 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Targeted Therapeutic Area
  • Figure 8.9 Clinical Trial Analysis: Distribution by Study Design
  • Figure 8.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011 to 2020 (Till August)
  • Figure 8.11 Clinical Trial Analysis: Distribution by Geography
  • Figure 8.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 8.13 Clinical Trial Analysis: Distribution by Trial Registration Year, Trial Recruitment Status and Geography
  • Figure 8.14 Most Active Players: Distribution by Number of Clinical Trials
  • Figure 8.15 Most Active Connected / Smart Drug Delivery Devices and Add-On Sensors: Distribution by Number of Clinical Trials
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (Till August)
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Type of Device
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type and Year of Partnership
  • Figure 9.5 Most Active Players: Distribution by Number of Partnership
  • Figure 9.6 Partnerships and Collaborations: Distribution by Geography
  • Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Trend 2015-2020 (Till August)
  • Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2015-2020 (Till August)
  • Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested (USD Million) by Type of Funding, 2015-2020 (Till August)
  • Figure 10.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2015-2020 (Till August)
  • Figure 10.6 Funding and Investment Analysis: Summary of Investments (USD Million), 2015-2020 (Till August)
  • Figure 10.7 Funding and Investment Analysis: Distribution by Year of Investments and Number of Funding Instances, Across Major Device Categories, 2015-2020 (Till August)
  • Figure 10.8 Funding and Investment Analysis: Amount Invested by Year of Investment, Across Major Device Categories, 2015-2020 (Till August)
  • Figure 10.9 Most Active Players: Distribution by Number of Funding Instances, 2015-2020 (Till August)
  • Figure 10.10 Most Active Players: Distribution by Amount Invested (USD Million), 2015-2020 (Till August)
  • Figure 10.11 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 10.12 Funding and Investments: Distribution by Amount Invested (USD Million) and Geography
  • Figure 11.1 Value Chain Analysis: Connected / Smart Drug Delivery Devices Value Chain
  • Figure 11.2 Value Chain Analysis: Cost Distribution Across Value Chain
  • Figure 11.3 Costs Associated with Concept Development and Proof of Concept
  • Figure 11.4 Costs Associated with Research and Product Development
  • Figure 11.5 Costs Associated with Clinical Trials
  • Figure 11.6 Costs Associated with Regulatory Approvals
  • Figure 11.7 Costs Associated with Manufacturing and Product Assembly
  • Figure 11.8 Costs Associated with Application Development
  • Figure 11.9 Costs Associated with Marketing and Sales
  • Figure 12.1 Global Connected / Smart Drug Delivery Systems Market, 2020-2030 (USD Million)
  • Figure 12.2 Connected / Smart Drug Delivery Systems Market for Drug Delivery Devices, 2020-2030 (By Value)
  • Figure 12.3 Connected / Smart Drug Delivery Systems Market for Add-On Sensors, 2020-2030 (By Value)
  • Figure 12.4 Global Connected / Smart Drug Delivery Systems Market, 2020-2030 (Million Units)
  • Figure 12.5 Connected / Smart Drug Delivery Systems Market for Drug Delivery Devices, 2020-2030 (By Volume)
  • Figure 12.6 Connected / Smart Drug Delivery Systems Market for Add-On Sensors, 2020-2030 (By Volume)
  • Figure 12.7 Connected / Smart Drug Delivery Systems Market in North America, 2020-2030 (USD Million)
  • Figure 12.8 Connected /Smart Drug Delivery Systems Market in Europe, 2020-2030 (USD Million)
  • Figure 12.9 Connected /Smart Drug Delivery Systems Market in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.10 Connected / Smart Drug Delivery Systems Market in MENA, 2020-2030 (USD Million)
  • Figure 12.11 Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.12 Connected / Smart Drug Delivery Systems Market in North America, 2020-2030 (Million Units)
  • Figure 12.13 Connected / Smart Drug Delivery Systems Market in Europe, 2020-2030 (Million Units)
  • Figure 12.14 Connected / Smart Drug Delivery Systems Market in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.15 Connected / Smart Drug Delivery Systems Market in MENA, 2020-2030 (Million Units)
  • Figure 12.16 Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.17 Connected / Smart Drug Delivery Systems Market for Inhalers, 2020-2030 (USD Million)
  • Figure 12.18 Connected / Smart Drug Delivery Systems Market for Inhalers in North America, 2020-2030 (USD Million)
  • Figure 12.19 Connected / Smart Drug Delivery Systems Market for Inhalers in Europe, 2020-2030 (USD Million)
  • Figure 12.20 Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.21 Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, 2020-2030 (USD Million)
  • Figure 12.22 Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America Rest of the World, 2020-2030 (USD Million)
  • Figure 12.23 Connected / Smart Drug Delivery Systems Market for Handheld Injectors, 2020-2030 (USD Million)
  • Figure 12.24 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, 2020-2030 (USD Million)
  • Figure 12.25 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, 2020-2030 (USD Million)
  • Figure 12.26 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.27 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, 2020-2030 (USD Million)
  • Figure 12.28 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.29 Connected / Smart Drug Delivery Systems Market for Wearable Injectors, 2020-2030 (USD Million)
  • Figure 12.30 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, 2020-2030 (USD Million)
  • Figure 12.31 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, 2020-2030 (USD Million)
  • Figure 12.32 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.33 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, 2020-2030 (USD Million)
  • Figure 12.34 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.35 Connected / Smart Drug Delivery Systems Market for Inhalers, 2020-2030 (Million Units)
  • Figure 12.36 Connected / Smart Drug Delivery Systems Market for Inhalers in North America, 2020-2030 (Million Units)
  • Figure 12.37 Connected / Smart Drug Delivery Systems Market for Inhalers in Europe, 2020-2030 (Million Units)
  • Figure 12.38 Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.39 Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, 2020-2030 (Million Units)
  • Figure 12.40 Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America Rest of the World, 2020-2030 (Million Units)
  • Figure 12.41 Connected / Smart Drug Delivery Systems Market for Handheld Injectors, 2020-2030 (Million Units)
  • Figure 12.42 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, 2020-2030 (Million Units)
  • Figure 12.43 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, 2020-2030 (Million Units)
  • Figure 12.44 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.45 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, 2020-2030 (Million Units)
  • Figure 12.46 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.47 Connected / Smart Drug Delivery Systems Market for Wearable Injectors, 2020-2030 (Million Units)
  • Figure 12.48 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, 2020-2030 (Million Units)
  • Figure 12.49 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, 2020-2030 (Million Units)
  • Figure 12.50 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, 2020-2030 (Million Units
  • Figure 12.51 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, 2020-2030 (Million Units)
  • Figure 12.52 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.53 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, 2020-2030 (USD Million)
  • Figure 12.54 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, 2020-2030 (USD Million)
  • Figure 12.55 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, 2020-2030 (USD Million)
  • Figure 12.56 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.57 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, 2020-2030 (USD Million)
  • Figure 12.58 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.59 Connected / Smart Drug Delivery Systems Market for Neurological Disorders, 2020-2030 (USD Million)
  • Figure 12.60 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, 2020-2030 (USD Million)
  • Figure 12.61 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, 2020-2030 (USD Million)
  • Figure 12.62 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.63 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in MENA, 2020-2030 (USD Million)
  • Figure 12.64 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.65 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, 2020-2030 (USD Million)
  • Figure 12.66 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, 2020-2030 (USD Million)
  • Figure 12.67 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, 2020-2030 (USD Million)
  • Figure 12.68 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.69 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, 2020-2030 (USD Million)
  • Figure 12.70 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, 2020-2030 (USD Million)
  • Figure 12.71 Connected / Smart Drug Delivery Systems Market for Other Disorders, 2020-2030 (USD Million)
  • Figure 12.72 Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, 2020-2030 (USD Million)
  • Figure 12.73 Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, 2020-2030 (USD Million)
  • Figure 12.74 Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 12.75 Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, 2020-2030 (USD Million)
  • Figure 12.76 Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, 2018-2030 (USD Million)
  • Figure 12.77 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, 2020-2030 (Million Units)
  • Figure 12.78 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, 2020-2030 (Million Units)
  • Figure 12.79 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, 2020-2030 (Million Units)
  • Figure 12.80 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.81 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, 2020-2030 (Million Units)
  • Figure 12.82 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.83 Connected / Smart Drug Delivery Systems Market for Neurological Disorders, 2020-2030 (Million Units)
  • Figure 12.84 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, 2020-2030 (Million Units)
  • Figure 12.85 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, 2020-2030 (Million Units)
  • Figure 12.86 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.87 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in MENA, 2020-2030 (Million Units)
  • Figure 12.88 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.89 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, 2020-2030 (Million Units)
  • Figure 12.90 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, 2020-2030 (Million Units)
  • Figure 12.91 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, 2020-2030 (Million Units)
  • Figure 12.92 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.93 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, 2020-2030 (Million Units)
  • Figure 12.94 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, 2020-2030 (Million Units)
  • Figure 12.95 Connected / Smart Drug Delivery Systems Market for Other Disorders, 2020-2030 (Million Units)
  • Figure 12.96 Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, 2020-2030 (Million Units)
  • Figure 12.97 Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, 2020-2030 (Million Units)
  • Figure 12.98 Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, 2020-2030 (Million Units)
  • Figure 12.99 Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, 2020-2030 (Million Units)
  • Figure 12.100 Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, 2018-2030 (Million Units)
  • Figure 12.101 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, 2018-2030 (USD Million)
  • Figure 12.102 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, 2018-2030 (USD Million)
  • Figure 12.103 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, 2018-2030 (USD Million)
  • Figure 12.104 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (USD Million)
  • Figure 12.105 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in MENA, 2018-2030 (USD Million)
  • Figure 12.106 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, 2018-2030 (USD Million)
  • Figure 12.107 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications, 2020-2030 (USD Million)
  • Figure 12.108 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, 2018-2030 (USD Million)
  • Figure 12.109 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (USD Million)
  • Figure 12.110 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (USD Million)
  • Figure 12.111 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, 2018-2030 (USD Million)
  • Figure 12.112 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, 2018-2030 (USD Million)
  • Figure 12.113 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, 2018-2030 (Million Units)
  • Figure 12.114 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, 2018-2030 (Million Units)
  • Figure 12.115 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, 2018-2030 (Million Units)
  • Figure 12.116 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (Million Units)
  • Figure 12.117 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in MENA, 2018-2030 (Million Units)
  • Figure 12.118 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, 2018-2030 (Million Units)
  • Figure 12.119 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications, 2020-2030 (Million Units)
  • Figure 12.120 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, 2018-2030 (Million Units)
  • Figure 12.121 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (Million Units)
  • Figure 12.122 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (Million Units)
  • Figure 12.123 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, 2018-2030 (Million Units)
  • Figure 12.124 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, 2018-2030 Million Units)
  • Figure 13.1 Connected Drug Delivery Systems Market, 2020-2030: COVID-19 Impact Informed Scenario (USD Billion)
  • Figure 14.1 Global Regulations Related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
  • Figure 14.2 USFDA: Approval Pathway for Combination Products
  • Figure 14.3 Health Canada: Approval Pathway for Combination Products
  • Figure 14.4 CFDA: Approval Pathway of Combination Products
  • Figure 14.5 Security of Data Captured in Connected Drug Delivery Devices: Key Steps that Need to be Undertaken for Managing Privacy
  • Figure 15.1 Global Prevalence of Diabetes
  • Figure 15.2 Evolution of Drug Delivery / Connected Devices Intended for Diabetes
  • Figure 15.3 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
  • Figure 15.4 Global Prevalence of Asthma
  • Figure 15.5 Evolution of Drug Delivery / Connected Devices Intended for Asthma
  • Figure 15.6 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthma Patients: Highlights on Twitter
  • Figure 16.1 Connected / Smart Drug Delivery Systems: SWOT Analysis
  • Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 17.1 Concluding Remarks: Connected / Smart Drug Delivery Systems and Add-On Sensors Market Landscape Summary
  • Figure 17.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 17.3 Concluding Remarks: Partnerships and Collaborations and Funding and Investment Analysis
  • Figure 17.4 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

  • Table 4.1 Connected / Smart Drug Delivery Systems: Information on Key Device Specifications
  • Table 4.2 Connected / Smart Drug Delivery Systems: List of Developers
  • Table 5.1 Add-On Sensors: Information on Key Device Specifications
  • Table 5.2 Add-On Sensors: List of Developers
  • Table 7.1 BIOCORP: Company Snapshot
  • Table 7.1 BIOCORP: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.3 BIOCORP: Recent Developments and Future Outlook
  • Table 7.4 Elcam Drug Delivery Devices (E3D): Company Snapshot
  • Table 7.5 Elcam Drug Delivery Devices (E3D): Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.6 Elcam Drug Delivery Devices (E3D): Recent Developments and Future Outlook
  • Table 7.7 Novo Nordisk: Company Snapshot
  • Table 7.8 Novo Nordisk: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.9 Novo Nordisk: Recent Developments and Future Outlook
  • Table 7.10 Merck: Company Snapshot
  • Table 7.11 Merck: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.12 Merck: Recent Developments and Future Outlook
  • Table 7.13 Pneuma Respiratory: Company Snapshot
  • Table 7.14 Pneuma Respiratory: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.15 Pneuma Respiratory: Recent Developments and Future Outlook
  • Table 7.16 H&T Presspart: Company Snapshot
  • Table 7.17 H&T Presspart: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.18 H&T Presspart: Recent Developments and Future Outlook
  • Table 7.19 Nemera: Company Snapshot
  • Table 7.20 Nemera: Connected / Smart Drug Delivery Devices Specific Portfolio
  • Table 7.21 Nemera: Recent Developments and Future Outlook
  • Table 9.1 Connected / Smart Drug Delivery Devices and Add-On Sensors: List of Partnerships, 2015-2020 (Till August)
  • Table 10.1 Connected / Smart Drug Delivery Devices and Add-On Sensors: Recent Funding Instances, 2015-2020 (Till August)
  • Table 10.2 Funding and Investment Analysis: Summary of Investments
  • Table 14.1 USFDA Centers for Drugs and Device Approval
  • Table 14.2 USFDA: Regulatory Review Timelines
  • Table 14.3 Regulatory Bodies in EU5 Countries
  • Table 14.4 SFDA: Regulatory Review Timelines
  • Table 19.1 Connected / Smart Drug Delivery Systems: Distribution by Type of Device
  • Table 19.2 Connected / Smart Drug Delivery Systems: Distribution by Status of Development
  • Table 19.3 Connected / Smart Drug Delivery Systems: Distribution by Mode of Drug Delivery
  • Table 19.4 Connected / Smart Drug Delivery Systems: Distribution by Route of Administration
  • Table 19.5 Connected / Smart Drug Delivery Systems: Distribution by Targeted Therapeutic Area
  • Table 19.6 Connected / Smart Drug Delivery Systems: Distribution by Key Device Specification
  • Table 19.7 Connected / Smart Drug Delivery Systems: Distribution by Availability of Audio / Visual Reminders
  • Table 19.8 Connected / Smart Drug Delivery Systems: Distribution by Type of Connectivity (USB, Bluetooth, NFC, WIFI, or Cellular)
  • Table 19.9 Connected / Smart Drug Delivery Systems: Distribution by Availability of Companion Mobile Application
  • Table 19.10 Connected / Smart Drug Delivery Systems: Distribution by Availability of Companion Web Portal
  • Table 19.11 Connected / Smart Drug Delivery Systems: Distribution by Availability of Data Storage / Cloud Platform
  • Table 19.12 Connected / Smart Drug Delivery Systems: Distribution by Availability of Rechargeable Battery / Battery Backup
  • Table 19.13 Connected / Smart Drug Delivery Systems: Distribution by Availability of Reminder / Notifications / Alerts
  • Table 19.14 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Systems
  • Table 19.15 Connected / Smart Drug Delivery System Developers: Distribution of Developers by Year of Establishment
  • Table 19.16 Connected / Smart Drug Delivery System Developers: Distribution of Developers by Company Size
  • Table 19.17 Connected / Smart Drug Delivery System Developers: Distribution of Developers by Location of Headquarters
  • Table 19.18 Connected / Smart Inhalers: Distribution by Status of Development
  • Table 19.19 Connected / Smart Inhalers: Distribution by Key Device Specifications
  • Table 19.20 Connected / Smart Inhaler Developers: Distribution by Year of Establishment
  • Table 19.21 Connected / Smart Inhaler Developers: Distribution by Company Size
  • Table 19.22 Connected / Smart Inhaler Developers: Distribution by Location of Headquarters
  • Table 19.23 Connected / Smart Handheld Injectors: Distribution by Status of Development
  • Table 19.24 Connected / Smart Handheld Injectors: Distribution by Key Device Specifications
  • Table 19.25 Connected / Smart Handheld Injector Developers: Distribution by Year of Establishment
  • Table 19.26 Connected / Smart Handheld Injector Developers: Distribution by Company Size
  • Table 19.27 Connected / Smart Handheld Injector Developers: Distribution by Location of Headquarters
  • Table 19.28 Connected / Smart Wearable Injectors: Distribution by Status of Development
  • Table 19.29 Connected / Smart Wearable Injectors: Distribution by Key Device Specifications
  • Table 19.30 Connected / Smart Wearable Injector Developers: Distribution by Year of Establishment
  • Table 19.31 Connected / Smart Wearable Injector Developers: Distribution by Company Size
  • Table 19.32 Connected / Smart Wearable Injector Developers: Distribution by Location of Headquarters
  • Table 19.33 Add-On Sensors: Distribution by Status of Development
  • Table 19.34 Add-On Sensors: Distribution by Area of Application
  • Table 19.35 Add-On Sensors: Distribution by Type of Connectivity Solution
  • Table 19.36 Add-On Sensors: Distribution by Key Device Specifications
  • Table 19.37 Add-On Sensors Developers: Distribution by Year of Establishment
  • Table 19.38 Add-On Sensors Developers: Distribution by Company Size
  • Table 19.39 Add-On Sensors: Distribution of Developers by Location of Headquarters
  • Table 19.40 Most Active Players: Distribution by Number of Add-On Sensors Offered
  • Table 19.41 Clinical Trial Analysis: Distribution by Type of Device
  • Table 19.42 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020 (Till August)
  • Table 19.43 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
  • Table 19.44 Clinical Trial Analysis: Distribution by Trial Status
  • Table 19.45 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 19.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 19.47 Clinical Trial Analysis: Distribution by Number of Trials and Targeted Therapeutic Area
  • Table 19.48 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Targeted Therapeutic Area
  • Table 19.49 Clinical Trial Analysis: Distribution by Study Design
  • Table 19.50 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled , Pre-2011 to 2020 (Till August)
  • Table 19.51 Clinical Trial Analysis: Distribution by Geography
  • Table 19.52 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 19.53 Clinical Trial Analysis: Distribution by Trial Registration Year, Trial Recruitment Status and Geography
  • Table 19.54 Most Active Players: Distribution by Number of Clinical Trials
  • Table 19.55 Most Active Connected / Smart Drug Delivery Devices and Add-On Sensors: Distribution by Number of Clinical Trials
  • Table 19.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (Till August)
  • Table 19.57 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 19.58 Partnerships and Collaborations: Distribution by Type of Device
  • Table 19.59 Most Active Players: Distribution by Number of Partnership
  • Table 19.60 Partnerships and Collaborations: Distribution by Type and Year of Partnership
  • Table 19.61 Most Active Players: Distribution by Number of Partnership
  • Table 19.62 Partnerships and Collaborations: Distribution by Geography
  • Table 19.63 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 19.64 Funding and Investment Analysis: Cumulative Year-wise Trend 2015-2020 (Till August)
  • Table 19.65 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2015-2020 (Till August)
  • Table 19.66 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 19.67 Funding and Investment Analysis: Distribution of Total Amount Invested (USD Million) by Type of Funding, 2015-2020 (Till August)
  • Table 19.68 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2015-2020 (Till August)
  • Table 19.69 Funding and Investment Analysis: Summary of Investments (USD Million), 2015-2020 (Till August)
  • Table 19.70 Funding and Investment Analysis: Distribution by Year of Investments and Number of Funding Instances, Across Major Device Categories, 2015-2020 (Till August)
  • Table 19.71 Funding and Investment Analysis: Amount Invested by Year of Investment, Across Major Device Categories, 2015-2020 (Till August)
  • Table 19.71 Most Active Players: Distribution by Number of Funding Instances, 2015-2020 (Till August)
  • Table 19.72 Most Active Players: Distribution by Amount Invested (USD Million), 2015-2020 (Till August)
  • Table 19.73 Most Active Investors: Distribution by Number of Funding Instances
  • Table 19.74 Funding and Investments: Distribution by Amount Invested (USD Million) and Geography
  • Table 19.75 Value Chain Analysis: Cost Distribution Across Value Chain
  • Table 19.76 Global Connected / Smart Drug Delivery Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030, (USD Million)
  • Table 19.77 Global Connected / Smart Drug Delivery Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
  • Table 19.78 Connected / Smart Drug Delivery Systems Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.79 Connected / Smart Drug Delivery Systems Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.80 Connected / Smart Drug Delivery Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.81 Connected / Smart Drug Delivery Systems Market in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.82 Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.83 Connected / Smart Drug Delivery Systems Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.84 Connected / Smart Drug Delivery Systems Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.85 Connected / Smart Drug Delivery Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.86 Connected / Smart Drug Delivery Systems Market in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.87 Connected / Smart Drug Delivery Systems Market in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.88 Connected / Smart Inhalers Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.89 Connected / Smart Drug Delivery Systems Market for Inhalers in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.80 Connected / Smart Inhalers Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.90 Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.91 Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.92 Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.93 Connected / Smart Drug Delivery Systems Market for Handheld Injectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.94 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.95 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.96 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.97 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.98 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.99 Connected / Smart Drug Delivery Systems Market for Wearable Injectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.100 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.101 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.102 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.103 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.104 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.105 Connected / Smart Drug Delivery Systems Market for Inhalers, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.106 Connected / Smart Drug Delivery Systems Market for Inhalers in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.107 Connected / Smart Drug Delivery Systems Market for Inhalers in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.108 Connected / Smart Drug Delivery Systems Market for Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.109 Connected / Smart Drug Delivery Systems Market for Inhalers in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.110 Connected / Smart Drug Delivery Systems Market for Inhalers in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.111 Connected / Smart Drug Delivery Systems Market for Handheld Injectors, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.112 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.113 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.114 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.115 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.116 Connected / Smart Drug Delivery Systems Market for Handheld Injectors in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.117 Connected / Smart Drug Delivery Systems Market for Wearable Injectors, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.118 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.119 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.120 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.121 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.122 Connected / Smart Drug Delivery Systems Market for Wearable Injectors in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.123 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.124 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.125 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.126 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.127 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.128 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.129 Connected / Smart Drug Delivery Systems Market for Neurological Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.130 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.131 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.132 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.131 Connected / Smart Drug Delivery Systems Market for Neurological Disorders MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.132 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.133 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.134 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.135 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.136 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.137 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.139 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.140 Connected / Smart Drug Delivery Systems Market for Other Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.141 Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.142 Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.143 Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.144 Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.145 Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.146 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.147 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.148 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.149 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.150 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.151 Connected / Smart Drug Delivery Systems Market for Metabolic Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.152 Connected / Smart Drug Delivery Systems Market for Neurological Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.153 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.154 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.155 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.156 Connected / Smart Drug Delivery Systems Market for Neurological Disorders MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.157 Connected / Smart Drug Delivery Systems Market for Neurological Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.158 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.159 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.160 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.161 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.162 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.163 Connected / Smart Drug Delivery Systems Market for Respiratory Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.164 Connected / Smart Drug Delivery Systems Market for Other Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.165 Connected / Smart Drug Delivery Systems Market for Other Disorders in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.166 Connected / Smart Drug Delivery Systems Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.167 Connected / Smart Drug Delivery Systems Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.168 Connected / Smart Drug Delivery Systems Market for Other Disorders in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.169 Connected / Smart Drug Delivery Systems Market for Other Disorders in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.170 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.171 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.172 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.173 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.174 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.175 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.176 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.177 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.178 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.179 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.180 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.181 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.182 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.183 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenario, 2020-2030 Million Units)
  • Table 19.184 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.185 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.186 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.187 Connected / Smart Drug Delivery Systems Market for Products Intended for Injectables in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 Million Units)
  • Table 19.188 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenario, 2020-2030 Million Units)
  • Table 19.189 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.190 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.191 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.192 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in MENA, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)
  • Table 19.193 Connected / Smart Drug Delivery Systems Market for Products Intended for Inhalable Medications in Latin America and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (Million Units)

List Of Companies

  • 1. 3E Bioventures Capital
  • 2. 3M
  • 3. 5AM Ventures
  • 4. A. Menarini Diagnostics
  • 5. Abbott
  • 6. Academic Pediatric Association
  • 7. Adherium
  • 8. Adocia
  • 9. Aerobit Health
  • 10. AgaMatrix
  • 11. Aguettant
  • 12. AIRBRIO
  • 13. Airnest
  • 14. Allegheny Health Network
  • 15. AMC Health
  • 16. Amiko
  • 17. Andaluz Health Service
  • 18. Anthem Blue Cross and Blue Shield
  • 19. Apellis Pharmaceuticals
  • 20. Aptar Pharma
  • 21. Aristotle University of Thessaloniki
  • 22. ARTORG Center
  • 23. Asante Solutions
  • 24. Asthma and Respiratory Foundation NZ
  • 25. AstraZeneca
  • 26. Australasian Medical & Scientific
  • 27. Bank of China Group Investment
  • 28. Barbara Davis Center
  • 29. Bayer
  • 30. Becton Dickinson
  • 31. Bigfoot Biomedical
  • 32. BioAdvance
  • 33. BIOCORP
  • 34. BioScience Managers
  • 35. Black Pearls
  • 36. Blackstone Life Sciences
  • 37. Blue Cross and Blue Shield
  • 38. Boehringer Ingelheim
  • 39. Robert Bosch Venture Capital
  • 40. Bosman Medical Devices
  • 41. Boston Children's Hospital
  • 42. Breed Reply
  • 43. Calgary Health Trust
  • 44. Cam Med
  • 45. Cambridge Consultants
  • 46. Cambridge University Hospitals
  • 47. Capital Royalty Partners II
  • 48. Centre Hospitalier de Luxembourg
  • 49. Chengdu Municipal Government
  • 50. Children's Hospital of Philadelphia
  • 51. Christchurch Clinical Studies Trust
  • 52. Chronicare
  • 53. Cincinnati Children's Hospital
  • 54. CincyTech
  • 55. Cintrifuse
  • 56. Cleveland Clinic
  • 57. Cognita Labs
  • 58. Cohero Health
  • 59. Common Sensing
  • 60. Companion Medical
  • 61. Connecticut Children's Medical Center
  • 62. Cormorant Asset Management
  • 63. Crux Product Design
  • 64. Debiotech
  • 65. Desert Oasis Healthcare
  • 66. Dexcom
  • 67. Diabeloop
  • 68. Diabnext
  • 69. DreaMed Diabetes
  • 70. E3D Elcam Drug Delivery Devices
  • 71. Eli Lilly
  • 72. EMD Serono
  • 73. Emory University
  • 74. Emperra
  • 75. Enable Injections
  • 76. EOFlow
  • 77. etectRx
  • 78. Eularis
  • 79. International Diabetes Federation
  • 80. Express Scripts
  • 81. Fenway Health
  • 82. Fidelity International
  • 83. FindAir
  • 84. Fitbit
  • 85. Flex Digital Health
  • 86. Gecko Health (acquired by Teva Pharmaceuticals)
  • 87. Genentech
  • 88. Gerresheimer
  • 89. Gilead Sciences
  • 90. GIS Strategic Ventures
  • 91. Glooko
  • 92. Gloria Pharmaceuticals
  • 93. GlucoRx
  • 94. GSK
  • 95. H&T Presspart
  • 96. Haisco Pharmaceutical
  • 97. Hamad Medical
  • 98. Harvard University
  • 99. Haselmeier
  • 100. Health Innovations
  • 101. Health2Sync
  • 102. HealthPartners Institute
  • 103. HealthPrize Technologies
  • 104. Heitkamp & Thumann Group
  • 105. HGE Health
  • 106. Hikma Ventures
  • 107. Hoffmann-La Roche
  • 108. HP Labs
  • 109. Huons
  • 110. IBM
  • 111. Idea Bridge
  • 112. ImagineCare
  • 113. Imperial College London
  • 114. Indiana University
  • 115. INKEF Capital
  • 116. Innovation Zed
  • 117. Institut de Recherches Cliniques de Montreal
  • 118. Insulclock
  • 119. Insulcoud S.L.
  • 120. Insulet
  • 121. International Clinical Trials Association
  • 122. International Diabetes Center at Park Nicollet
  • 123. Investitionsbank des Landes Brandenburg
  • 124. Invest-NL
  • 125. iSage Rx
  • 126. i-SENS
  • 127. iSense
  • 128. Ismanis Engineering
  • 129. Jaeb Center for Health Research
  • 130. Janus Henderson
  • 131. JDRF T1D Fund
  • 132. Joslin Diabetes Center
  • 133. Juvenile Diabetes Research Foundation
  • 134. K2 HealthVentures
  • 135. Kali Care
  • 136. Kap Code
  • 137. K-Bio Health
  • 138. Klue
  • 139. Kreos Capital
  • 140. LB Investment
  • 141. Leads Biolabs
  • 142. Legacy Health
  • 143. LEO Pharma
  • 144. Life Sciences Partners
  • 145. LINDAL Group
  • 146. Lupin
  • 147. Luz Saúde
  • 148. The University of Manchester
  • 149. McKesson Ventures
  • 150. MedCrypt
  • 151. Medical International Research
  • 152. Medical Research Institute of New Zealand
  • 153. Medical University of Graz
  • 154. Medical University of South Carolina
  • 155. Medtronic
  • 156. Medtrum
  • 157. Merck KGaA
  • 158. MidMichigan Health
  • 159. Mode
  • 160. Molina Healthcare
  • 161. Monaghan Medical Corporation
  • 162. Morningside Venture Capital
  • 163. Mountain Diabetes and Endocrine Center
  • 164. Movi
  • 165. mySugr
  • 166. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • 167. National Institutes of Health
  • 168. National Library of Medicine (NLM)
  • 169. Navia Life Care
  • 170. Nemera
  • 171. Nemours
  • 172. New World Health
  • 173. New Zealand Medical & Scientific
  • 174. nGageIT Digital Health Solutions
  • 175. NHS Foundation Trust
  • 176. Noble International
  • 177. Nordic Infucare
  • 178. Northwestern University
  • 179. Norton Healthcare
  • 180. Novartis
  • 181. Novo Nordisk
  • 182. National Science Foundation
  • 183. Nutrino Health (acquired by Medtronic)
  • 184. Ohio Innovation Fund
  • 185. OMRON Healthcare
  • 186. One Drop
  • 187. One Funds Management
  • 188. Oregon Health and Science University
  • 189. ORI Healthcare Fund
  • 190. Orion
  • 191. Otsuka Pharmaceutical
  • 192. Owen Mumford
  • 193. Owsley Brown Charitable Foundation
  • 194. P5 Health Ventures
  • 195. Patients Know Best
  • 196. Pendiq
  • 197. Peppermint VenturePartners
  • 198. PercuSense
  • 199. PharmaSens
  • 200. Planet Innovation
  • 201. Pneuma Respiratory
  • 202. Portal Instruments
  • 203. ProCare
  • 204. Propeller Health
  • 205. Proteus Digital Health
  • 206. Quadrant Capital Advisors
  • 207. Qualcomm
  • 208. Qualicaps
  • 209. QuiO
  • 210. Quotient Sciences
  • 211. Rabin Medical Center
  • 212. Reciprocal Labs
  • 213. ResMed
  • 214. Respia
  • 215. Rimidi
  • 216. Roche
  • 217. Philips
  • 218. Rubin Medical
  • 219. Safeguard Scientifics
  • 220. Sagentia
  • 221. Samsung
  • 222. Sanner
  • 223. Sanofi
  • 224. Sansum Diabetes Research Institute
  • 225. Schneider Children's Medical Center
  • 226. Senseonics
  • 227. Sensile Medical
  • 228. Senvest Capital
  • 229. Sequoia Capital China
  • 230. SFC Fluidics
  • 231. SHL Medical
  • 232. Sidra Medicine
  • 233. Sirma Medical Systems
  • 234. Smartgateways
  • 235. Smile
  • 236. Sonceboz
  • 237. Sonmol
  • 238. SOOIL Development
  • 239. Sorrel Medical
  • 240. SQ Innovation
  • 241. SR One
  • 242. Stanford University
  • 243. Stevanato Group
  • 244. Summatix
  • 245. Sunrise Labs
  • 246. Swanhill Capital
  • 247. Syneos Health
  • 248. T1D Exchange
  • 249. Takeda Pharmaceutical
  • 250. Tandem Diabetes Care
  • 251. Teva Pharmaceuticals
  • 252. Texas Diabetes & Endocrinology
  • 253. The Leeds Teaching Hospitals
  • 254. Massachusetts Life Sciences Center (MLSC)
  • 255. Théa Group
  • 256. Theras
  • 257. Three Leaf Ventures
  • 258. Tidepool
  • 259. Timesulin
  • 260. Trade Capital Funding
  • 261. Trudell Medical
  • 262. TypeZero Technologies (acquired by Dexcom)
  • 263. UCB
  • 264. UnitedHealth
  • 265. Grenoble Alpes University Hospital
  • 266. University of Alabama
  • 267. University of Calgary
  • 268. University of California
  • 269. University of Cambridge
  • 270. University of Colorado
  • 271. University of Edinburgh
  • 272. University of Florida
  • 273. University of Ljubljana
  • 274. University of Minnesota
  • 275. University of Padova
  • 276. University of Pennsylvania
  • 277. University of Virginia
  • 278. Vatel Capital
  • 279. Vectura Group
  • 280. Verily
  • 281. ViCentra
  • 282. Visionnaire Ventures
  • 283. Vitalus Health
  • 284. Waterline Ventures
  • 285. Welkin Health
  • 286. West Pharmaceutical Services
  • 287. Xeris Pharmaceuticals
  • 288. Yale University
  • 289. Ypsomed
  • 290. Zaffre Investments
  • 291. Zealand Pharma
  • 292. Zhangjiang Venture Investment